Skip to content

BioMarin Pharmaceuticals BMRN Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$520.42M-20.8%$657.24M+25.5%$523.88M+22.7%
$73.9M-7.1%$79.56M-3.8%$82.73M-0.6%$83.25M-8.7%$91.15M-5.5%
$187.17M+3.2%$181.41M-2.7%$186.42M+3.2%$180.64M-0.2%$181.02M-10.2%
$874.25M+5.6%$827.99M-9.4%$913.98M+19.2%$766.77M+9.5%$700.26M+22.2%
$107.19M+4.0%$103.04M+25.9%$81.85M+13.9%$71.86M-5.6%$76.09M-10.9%
$339.52M+182%-$414.24M-40.2%-$295.39M
$806.4M+1,870%-$45.55M
$2.02B+449%$368.84M-35.8%$574.66M+138%$241.67M-19.9%$301.81M+60.8%
$767.06M+5.8%$724.96M-12.9%$832.13M+19.7%$694.91M+11.3%$624.18M+28.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does BioMarin Pharmaceuticals generate?
BioMarin Pharmaceuticals (BMRN) generated $874.3M in operating cash flow over the trailing twelve months.
What is BioMarin Pharmaceuticals's free cash flow?
After $107.2M of capital expenditures, BioMarin Pharmaceuticals's free cash flow was $767.1M over the trailing twelve months, up 22.9% year over year.
Where does BioMarin Pharmaceuticals's cash flow data come from?
Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.